The drug reprofiling strategy (aka drug repurposing, indication expansion) discovers new uses for licensed drugs. Our aim is to develop and validate market blockbuster, safe and effective, small molecule cancer therapies and conduct clinical trials. Our drug discovery and reprofiling pipeline allows integration of existing epidemiological and clinical trial data to mitigate risks of clinical trial failure.
We identify electrophysiological cell membrane targetable mechanisms of carcinogenic cell signaling pathways and inhibit these with drugs indicated for diseases other than cancer. Our reprofiled small molecule drugs are novel inhibitors of key cell signaling pathways that have a causal link in carcinogenesis and cancer progression.
The company’s lead discovery pipeline identified novel electrogenic mechanism of Wnt signaling pathway which is critical for adenocarcinomas including colon, breast and prostate. This led to the identification of novel inhibitors of Wnt pathway termed membrane potential regulating compounds (MPRCs). By using high throughput electrophysiology, precise intracellular assays and sequencing, transgenic and xenograft animal models we developed our first reprofiled MPRC that will enter Phase IIB clinical trials shortly for multiple solid tumour indication.
Our drug discovery pipeline is deeply rooted in biological and epidemiological evidence interrogated using human and machine learning approaches and validated in robust electrophysiological, intracellular and in vivo models.